John Hancock Income Securities Trust (JHS) 14.61

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
John Hancock Income Securities Trust (JHS) 14.61 $JHS

John Hancock Closed-End Funds Declare Quarterly Distributions
PR Newswire - Wed Jun 01, 3:58PM CDT
The five John Hancock closed-end funds listed below declared their quarterly distributions today as follows:
HTY: 10.05 (-0.03), JHS: 14.61 (-0.08), MFC: 13.35 (-0.07), HEQ: 15.22 (-0.18), MFC.TO: 17.51 (-0.29), JHI: 17.29 (+0.02), BTO: 25.69 (-0.49)

John Hancock Closed-End Funds Release Earnings Data
PR Newswire - Fri May 27, 3:38PM CDT
The eight John Hancock Closed-End Funds listed in the table below announced earnings1 for the three months ended April 30, 2016. The same data for the comparable three month period ended April 30, 2015 is also available below.
HTY: 10.05 (-0.03), HTD: 24.63 (-0.01), HPI: 23.10 (-0.16), PDT: 17.27 (-0.21), JHS: 14.61 (-0.08), MFC: 13.35 (-0.07), MFC.TO: 17.51 (-0.29), JHI: 17.29 (+0.02), HPF: 22.52 (-0.19), HPS: 19.90 (-0.33)

John Hancock Income Securities Trust, John Hancock Investors Trust
PR Newswire - Wed Feb 03, 9:20PM CST
At their annual meetings held today, shareholders of John Hancock Income Securities Trust (NYSE: JHS) and John Hancock Investors Trust (NYSE: JHI), each a closed-end fund managed by John Hancock Advisers, LLC, elected the following thirteen Trustees to continue to serve as members of the Board of Trustees of JHS and JHI: Charles L. Bardelis, James R. Boyle, Craig Bromley, Peter S. Burgess, William H. Cunningham, Grace K. Fey, Theron S. Hoffman, Deborah C. Jackson, Hassell H. McClellan, James M. Oates, Steven R. Pruchansky, Gregory A. Russo, and Warren A. Thomson.
JHS: 14.61 (-0.08), MFC: 13.35 (-0.07), MFC.TO: 17.51 (-0.29), JHI: 17.29 (+0.02)

John Hancock closed-end funds renew share repurchase plans
M2 - Wed Dec 16, 5:43AM CST
John Hancock Financial Opportunities Fund (NYSE: BTO), John Hancock Hedged Equity & Income Fund (NYSE: HEQ), John Hancock Income Securities Trust (NYSE: JHS), John Hancock Premium Dividend Fund (NYSE: PDT) and John Hancock Tax-Advantaged Dividend Income Fund (NYSE: HTD) said the board of trustees has renewed the funds' share repurchase plans, which are set to expire on December 31, 2015. The board of trustees approved the renewal of the share repurchase plans as part of its ongoing evaluation of options to enhance shareholder value and potentially decrease the discount between the market price and the net asset value (NAV) of the funds' common shares. Under the share repurchase plans, each fund may purchase, in the open market, between January 1, 2016 and December 31, 2016, up to an additional 10 percent of its outstanding common shares (based on common shares outstanding as of December 31, 2015). Year-to-date through November 30, 2015, the Funds have repurchased the following amount of shares : HEQ repurchased 1,120,307 shares (or 8.21 percent of the outstanding shares), contributing to its NAV by approximately USD0.182; JHS repurchased 96,519 shares (or 0.82 percent of outstanding shares), contributing to its NAV by approximately USD0.013; PDT repurchased 1,001,898 shares (or 2.10 percent of the outstanding shares), contributing to its NAV by approximately USD0.031; and HTD repurchased 1,341,340 shares (or 3.62 percent of the outstanding shares), contributing to its NAV by approximately USD0.094. BTO did not repurchase any shares for the year-to-date period through November 30, 2015. John Hancock Investments provides asset management services to individuals and institutions through a unique manager-of-managers approach. A wealth management business of John Hancock Financial, we managed USD127 billion in assets as of September 30, 2015, across mutual funds, college savings plans, and retirement plans. John Hancock Financial is a division of Manulife Financial, a leading Canada-based financial services group with principal operations in Asia, Canada and the United States. Operating as Manulife Financial in Canada and Asia, and primarily as John Hancock in the United States, the company offers clients a diverse range of financial protection products and wealth management services through its extensive network of employees, agents and distribution partners. Funds under management by Manulife Financial and its subsidiaries were CAD888 billion (USD663 billion) as of September 30, 2015.
HTD: 24.63 (-0.01), PDT: 17.27 (-0.21), JHS: 14.61 (-0.08), HEQ: 15.22 (-0.18), MFC: 13.35 (-0.07), BTO: 25.69 (-0.49)

John Hancock Closed-End Funds Announce Renewal of Share Repurchase Plans
PR Newswire - Thu Dec 10, 5:25PM CST
John Hancock Financial Opportunities Fund (NYSE: BTO), John Hancock Hedged Equity & Income Fund (NYSE: HEQ), John Hancock Income Securities Trust (NYSE: JHS), John Hancock Premium Dividend Fund (NYSE: PDT), and John Hancock Tax-Advantaged Dividend Income Fund (NYSE: HTD) (each a "Fund" and collectively, the "Funds" announced today that the Board of Trustees has renewed the Funds' share repurchase plans that are set to expire on December 31, 2015.
HTD: 24.63 (-0.01), PDT: 17.27 (-0.21), JHS: 14.61 (-0.08), HEQ: 15.22 (-0.18), MFC: 13.35 (-0.07), MFC.TO: 17.51 (-0.29), BTO: 25.69 (-0.49)

Four John Hancock Closed-End Funds Announce New Liquidity Facility Provider
PR Newswire - Wed Dec 02, 4:53PM CST
John Hancock Income Securities Trust (NYSE: JHS), John Hancock Investors Trust (NYSE: JHI), John Hancock Premium Dividend Fund (NYSE: PDT), and John Hancock Tax-Advantaged Dividend Income Fund (NYSE: HTD) (each the "Fund" and collectively, the "Funds", closed-end funds that utilize leverage, today announced a new liquidity facility provider.
HTD: 24.63 (-0.01), STT: 64.91 (-1.03), PDT: 17.27 (-0.21), JHS: 14.61 (-0.08), MFC: 13.35 (-0.07), MFC.TO: 17.51 (-0.29), JHI: 17.29 (+0.02)

John Hancock Closed-End Funds Announce Annual Shareholder Meeting And Record Dates
PR Newswire - Wed Sep 16, 4:48PM CDT
The ten John Hancock closed-end funds listed below announced today that each fund's Annual Meeting of Shareholders ("Annual Meeting" will be held on February 3, 2016, at 2:00 p.m., Eastern Time, at the offices of the funds, 601 Congress Street, Boston, Massachusetts 02210:
HTY: 10.05 (-0.03), HTD: 24.63 (-0.01), PDT: 17.27 (-0.21), HPI: 23.10 (-0.16), JHS: 14.61 (-0.08), HEQ: 15.22 (-0.18), MFC: 13.35 (-0.07), MFC.TO: 17.51 (-0.29), JHI: 17.29 (+0.02), BTO: 25.69 (-0.49), HPF: 22.52 (-0.19), HPS: 19.90 (-0.33)

John Hancock Income Securities Trust And John Hancock Investors Trust Announce Results Of Annual Meetings Of Shareholders
PR Newswire - Mon Jan 26, 6:37PM CST
At their annual meetings held today, shareholders of John Hancock Income Securities Trust (NYSE: JHS) and John Hancock Investors Trust (NYSE: JHI), each a closed-end fund managed by John Hancock Advisers, LLC, re-elected the following twelve Trustees as members of the Board of Trustees of JHS and JHI: Charles L. Bardelis, Craig Bromley, Peter S. Burgess, William H. Cunningham, Grace K. Fey, Theron S. Hoffman, Deborah C. Jackson, Hassell H. McClellan, James M. Oates, Steven R. Pruchansky, Gregory A. Russo, and Warren A. Thomson.
JHS: 14.61 (-0.08), MFC: 13.35 (-0.07), MFC.TO: 17.51 (-0.29), JHI: 17.29 (+0.02)

John Hancock closed-end funds announce distributions of dividends for quarter
M2 - Tue Dec 02, 3:15AM CST
The five John Hancock closed-end funds, Financial Opportunities Fund (NYSE:BTO); Hedged Equity & Income Fund (NYSE:HEQ); Investors Trust (NYSE:JHI); Income Securities Trust (NYSE:JHS); and Tax-Advantaged Global Shareholder Yield Fund (NYSE:HTY) revealed on Monday the payment of their quarterly distributions.
HTY: 10.05 (-0.03), JHS: 14.61 (-0.08), HEQ: 15.22 (-0.18), JHI: 17.29 (+0.02), BTO: 25.69 (-0.49)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Evotec’s $2.9M Grant Advances Drug Safety Tech

Updated Category News Views 87

Revitalizing Drug Development with Human Stem Cells Evotec's latest win—a crisp $2.9 million grant from the Gates Foundation—is like a shot of adrenaline for drug safety innovation. This isn't just another drop in the bucket; it's a solid boost toward improving how we screen potential drugs for fetal risks before they're tossed into the costly whirlpool of clinical...

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 399

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 448

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
Segway Powersports Dominates Baja 1000 with Class 2 Sweep

Updated Category News Views 72

Catching the eye of any betting man, Segway Powersports has turned its maiden outing at the relentless SCORE Baja 1000 into a rousing victory. Their arrival on this unforgiving stage with a one-two in Class 2 isn't just a lucky roll—you don't chance upon podium sweeps in such gritty contests. Dissecting the Drive: Commitment and Coordination Unfolding across Baja's...

Continue Reading
Pollo AI Unveils York AI: Automating Social Growth

Updated Category News Views 0

York AI Debuts as the New Kid on the Block Amid the hustle and bustle of a tech-savvy Singapore, Pollo AI’s latest offering, York AI, sashays onto the scene with the promise of putting social media growth on cruise control. We're talking about a digital sidekick that seems to know your online persona better than you do. It’s tailored for everyone from the small-time...

Continue Reading
Ascletis' Preclinical Successes: Future of Obesity Treatment

Updated Category News Views 14

Pharma Giants Eyeing a New Potential Well, it seems the world of pharma is buzzing with Ascletis’ latest developments in the obesity treatment arena. They’ve just showcased some intriguing preclinical data at ObesityWeek® 2026. The standout? A cocktail of advancements that might just put a dent in the obesity epidemic if further studies pan out. ASC30_48: A Daily...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 412

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Fapon's MEDICA 2026 Bid: Game-Changer or Same Old?

Updated Category News Views 89

Fapon's Ambitious Pitch at MEDICA: A Real Deal? MEDICA 2026 sees Fapon stepping up, laden with flashy promises and hardened expertise. Set up in Düsseldorf, these folks are pushing their Local Manufacturing Solutions harder than a door-to-door vacuum seller. The main pitch? Bolstering local IVD production with their comprehensive tech transfer services. How many outfits...

Continue Reading
Local Voices to Shape Mekong's Story in New Alliance

Updated Category News Views 284

Unpacking the New Storytelling Strategy Right off the bat, let's make it clear—this isn't just another run-of-the-mill environmental project announcement. When the National Geographic Society teams up with ThaiBev to empower Southeast Asian storytellers, they're not just waving around the usual conservation banner. Instead, they're betting on local voices to lead the...

Continue Reading
Akeso's Gumokimab Wins NMPA Approval for AS Treatment

Updated Category News Views 115

Gumokimab Approved: A New Dawn in AS Treatment Yeah, the biotech world shifts gears today as Akeso's gumokimab received the green light from China's National Medical Products Administration (NMPA). This approval for treating ankylosing spondylitis, or AS, isn't just another checkbox for Akeso; it's a game-changer in tackling this chronic inflammatory disease. Why should...

Continue Reading

Top 5 Most Recently Viewed Articles

O-I Glass Announces Participation in Citi’s 2025 Conference

Updated Category News Views 208

O-I Glass Participation in the 2025 Basic Materials Conference PERRYSBURG, Ohio — O-I Glass, Inc., known for its commitment to creating exceptional glass products, is set to participate in the upcoming Citi’s 2025 Basic Materials Conference. This significant event will take place on a Wednesday in December, and features notable presentations from O-I's leadership....

Continue Reading
Osmium Partners Proposes Strategic Plan for Articore Growth

Updated Category News Views 104

Osmium Partners Proposes a Four-Step Plan for Articore Osmium Partners has recently made headlines with their proposal for Articore, aiming to elevate shareholder value through a methodical four-step approach. This initiative is driven by Osmium's belief that Articore's current management strategy lacks direction and has resulted in missed opportunities for growth and...

Continue Reading
Amplify Energy Set to Shine at EnerCom Denver Conference 2025

Updated Category News Views 135

Amplify Energy’s Participation in EnerCom Denver Conference Amplify Energy Corp. is gearing up to participate in the renowned annual EnerCom Denver Conference in 2025. This event, known for bringing together leading experts and investors in the energy sector, offers Amplify a prime platform to showcase its strategic initiatives and growth potential. Focus on Investor...

Continue Reading
Safe Life Expands CPR Training and AED Services through Acquisition

Updated Category News Views 197

Safe Life Strengthens National Coverage for Life-Saving Training Safe Life has made a significant move by acquiring HeartCert, a company known for its specialization in automated external defibrillators (AEDs) and CPR training. This acquisition allows Safe Life to broaden its reach into the Midwest, enhancing its commitment to providing life-saving training and equipment...

Continue Reading
Express Scripts Challenges FTC's Drug Pricing Conclusions

Updated Category News Views 106

Express Scripts Files Lawsuit Against the FTC Express Scripts, a major player in the pharmacy benefit manager sector, has recently taken legal action against the U.S. Federal Trade Commission (FTC). This lawsuit stems from a report that criticizes the role of pharmacy benefit managers in the pricing of medications. Express Scripts contends that the report's conclusions...

Continue Reading